Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

Study finds abdominal fat as a risk factor for osteoporosis, bone loss in women

For years, it was believed that obese women were at lower risk for developing osteoporosis, and that excess body fat actually protected against bone loss. However, a study presented today at the annual meeting of the Radiological Society of North America (RSNA) found that having too much internal abdominal fat may, in fact, have a damaging effect on bone health.

30 Nov 2010

Common, overprescribed drugs lead to election dopiness and immaturity

As Bill Maher, New York Magazine, the Washington Post and countless cable news and Internet sources have pointed out, the 2010 midterm campaigns and elections seem to have brought to light an American electorate capable of shocking illogic, ignorance and even violence.

29 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

Children with high BMI have adverse heart disease risk factors at adolescence

Children who have a high body mass index (BMI) between 9 and 12 years of age are more likely to have high blood pressure, cholesterol and blood insulin levels (all risk factors for developing heart disease) by the time they reach adolescence, according to a study published today.

26 Nov 2010

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune Technologies & Bioressources Inc. subsidiary, Acasti Pharma Inc., reports the completion of its preclinical program designed to compare the lipid management effects of Acasti's drug candidate CaPre versus prescription drug Lovaza.

25 Nov 2010

Chronic high fat cholesterol diet may lead to Alzheimer's disease

Research from the Laboratory of Psychiatry and Experimental Alzheimers Research at the Medical University Innsbruck (Austria) demonstrated that chronic high fat cholesterol diet in rats exhibited pathologies similar to Alzheimer's disease. The results were published in Molecular Cellular Neuroscience with lead author Dr. Christian Humpel. The study was co-authored by PhD students, Celine Ullrich and Michael Pirchl, from the same Laboratory.

24 Nov 2010

aAetna announces pilot with MCNT to improve diabetes care

Aetna today announced a pilot with the Medical Clinic of North Texas aimed at improving the care of diabetic patients of Hispanic and African American descent.

23 Nov 2010

Impax initiates challenge of patents relating to WELCHOL

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by Daiichi Sankyo, Inc. in connection with its WELCHOL® (Colesevelam HCl) for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. That's the conclusion from the world's largest ever randomized trial in kidney disease.

22 Nov 2010

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. This can result in leg muscle pain when walking, disability, amputation, and poor quality of life. Blocked arteries found in people with P.A.D. can be a red flag that other arteries, including those in the heart and brain, may also be blocked - increasing the risk of a heart attack or stroke.

20 Nov 2010

Childhood obesity linked to adult metabolic abnormalities and cardiovascular disease

Mounting evidence linking childhood obesity to an increasing risk of obesity, heart disease, type 2 diabetes, and other cardiovascular and metabolic disorders in adulthood is clearly presented in a comprehensive review article in the current issue of Childhood Obesity, published by Mary Ann Liebert, Inc. The article is available free online.

19 Nov 2010

African Americans have faster rates of decline in kidney function

African Americans along with some groups of Hispanics have faster rates of decline in kidney function compared to white Americans, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

19 Nov 2010

Study compares effect on HT status in mid, late life on dementia risk

Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.

19 Nov 2010

Study suggests pomegranate juice can ward-off complications in kidney disease patients

Studies in recent years have claimed multiple health benefits of pomegranate juice, including that it is a good source of antioxidants and lowers both cholesterol and blood pressure, especially in diabetic and hypertensive patients.

19 Nov 2010

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.

19 Nov 2010

Despite progress in testing Americans for HIV, lack of federal/private insurance impedes expansion

With projections that human immunodeficiency virus (HIV) infection rates are increasing in some populations, former Surgeon General Dr. C. Everett Koop -- who charted the nation's policies on HIV/AIDS following the first deaths from AIDS in 1981 -- today issued a stern warning to the public health community: HIV/AIDS continues to be a major epidemic and requires a national mobilization to identify and provide immediate care for many Americans with HIV who remain undiagnosed -- an estimated 200,000 people.

18 Nov 2010

Gene transfer reduces and stabilizes plaque and decreases inflammation

A plaque-fighting gene - studied in various forms by researchers at the Cedars-Sinai Heart Institute for 18 years - has now been transferred intravenously to lab mice bred to model atherosclerosis (clogged arteries) in humans. Studies show the gene transfer reduced and stabilized plaque and decreased inflammation, key factors in cutting the risk of heart disease.

18 Nov 2010

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2010.

18 Nov 2010

Cholesterol News and Research

Further Reading

Study finds abdominal fat as a risk factor for osteoporosis, bone loss in women

Common, overprescribed drugs lead to election dopiness and immaturity

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Children with high BMI have adverse heart disease risk factors at adolescence

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Chronic high fat cholesterol diet may lead to Alzheimer's disease

aAetna announces pilot with MCNT to improve diabetes care

Impax initiates challenge of patents relating to WELCHOL

VYTORIN reduces major vascular events in patients with chronic kidney disease

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

Childhood obesity linked to adult metabolic abnormalities and cardiovascular disease

African Americans have faster rates of decline in kidney function

Study compares effect on HT status in mid, late life on dementia risk

Study suggests pomegranate juice can ward-off complications in kidney disease patients

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Despite progress in testing Americans for HIV, lack of federal/private insurance impedes expansion

Gene transfer reduces and stabilizes plaque and decreases inflammation

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News